You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Recruiting
  • NSCLC, Non Small Cell Lung Cancer
  • +9 more
  • Santa Monica, California
  • +22 more
2022-03-18
Mar 18, 2022
S
A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies
Recruiting
  • Breast Cancer
  • +3 more
  • Poziotinib Hydrochloride
  • Long Beach, California
    Pacific Shores Medical Group
2021-06-14
Jun 14, 2021
N
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
Recruiting
  • Solid Tumors
  • Los Angeles, California
  • +12 more
2021-11-19
Nov 19, 2021
N
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • +6 more
  • NZV930
  • +2 more
  • Tampa, Florida
  • +9 more
2021-12-17
Dec 17, 2021
J
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
Active, not recruiting
  • Neoplasm
  • Beijing, China
  • +5 more
2022-03-24
Mar 24, 2022
N
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies - 2020
Completed
Has Results
  • Triple Negative Breast Cancer
  • +3 more
  • Boston, Massachusetts
  • +19 more
2021-07-12
Jul 12, 2021
I
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
Recruiting
  • Metastatic Solid Tumor
  • M-CENK, Suspension for Infusion, Cryopreserved (M-CENK)
  • +2 more
  • El Segundo, California
  • +1 more
2022-03-29
Mar 29, 2022
N
Phase I/II Study of PDR001 in Patients With Advanced Malignancies - 2020
Completed
Has Results
  • Melanoma
  • +4 more
  • PDR001
  • Baltimore, Maryland
  • +40 more
2021-08-31
Aug 31, 2021
N
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. - 2020
Completed
Has Results
  • Advanced Solid Tumors
  • New York, New York
  • +23 more
2022-01-17
Jan 17, 2022
B
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Active, not recruiting
  • Neoplasms by Site
  • Relatlimab
  • +2 more
  • La Jolla, California
  • +52 more
2022-02-10
Feb 10, 2022
N
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Active, not recruiting
  • Solid Tumors
  • Los Angeles, California
  • +8 more
2022-04-05
Apr 5, 2022
P
Study of NEO-201 in Solid Tumors Expansion Cohorts
Recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • NEO-201 in combination with pembrolizumab
  • Bethesda, Maryland
    National Cancer Institute
2022-04-01
Apr 1, 2022
N
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Active, not recruiting
  • Advanced Malignancies
  • Baltimore, Maryland
  • +13 more
2022-03-18
Mar 18, 2022
N
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +4 more
  • Boston, Massachusetts
  • +8 more
2022-02-24
Feb 24, 2022
M
MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Active, not recruiting
  • Solid Tumors
  • MEDI9447
  • MEDI9447 and MEDI4736
  • La Jolla, California
  • +17 more
2022-01-18
Jan 18, 2022
N
A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
Active, not recruiting
  • Advanced Solid Tumors
  • Boston, Massachusetts
  • +13 more
2022-03-18
Mar 18, 2022
J
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Phase Ib ARRY-614 + nivolumab
  • +4 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
2022-01-09
Jan 9, 2022
N
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Recruiting
  • Carcinoma, Renal Cell
  • Duarte, California
  • +8 more
2022-03-18
Mar 18, 2022
B
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
Recruiting
  • Solid Tumor, Adult
  • Santa Monica, California
  • +5 more
2022-02-22
Feb 22, 2022
I
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Recruiting
  • Ovarian Cancer
  • +10 more
  • West Hollywood, California
  • +26 more
2022-04-06
Apr 6, 2022
A
A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors - 2019
Completed
  • Advanced Solid Tumors Cancer
  • Scottsdale, Arizona
  • +14 more
2020-07-17
Jul 17, 2020
D
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer - 2020
Terminated
  • Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer
  • +2 more
  • Boston, Massachusetts
  • +2 more
2022-03-16
Mar 16, 2022
N
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Recruiting
  • Advanced Solid Tumor
  • Huntersville, North Carolina
    Carolina BioOncology
2022-01-18
Jan 18, 2022
N
Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas - 2020
Terminated
  • Solid Tumors and Lymphomas
  • Los Angeles, California
  • +11 more
2021-10-07
Oct 7, 2021
I
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Active, not recruiting
  • Solid Tumor
  • Tucson, Arizona
  • +2 more
2022-02-15
Feb 15, 2022